Preclinical testing of possible combination therapies will also benefit from study of these mouse models to determine the effects of Eph expression and targeting on sensitisation to established therapies, as seen with trastuzumab resistance associated with EphA2 in HER2-positive breast cancer. This evidence concerns the gene EPHA2 and breast carcinoma.